Source: Υπουργείο Υγείας (CY) Revision Year: 2018 Publisher: Remedica Ltd, Aharnon Street, Limassol Industrial Estate, 3056 Limassol, Cyprus
Lacromid 200 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. White, round, scored film-coated tablets with Remedica’s logo on one side. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses. |
Each film-coated tablet contains bezafibrate 200 mg.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Bezafibrate |
Bezafibrate lowers elevated blood lipids (triglycerides and cholesterol). Elevated VLDL and LDL are reduced by treatment with bezafibrate, whilst HDL-levels are increased. Furthermore, cholesterol biosynthesis is reduced by bezafibrate, which is accompanied by a stimulation of the LDL receptor-mediated lipoprotein catabolism. |
| List of Excipients |
|---|
|
Core: Povidone Coating: Hypromellose |
PVC/Aluminium Blisters. Pack-size of 50 and 1000 film-coated tablets.
PP containers with PE closure. Pack-size 50 and 1000 film-coated tablets.
Not all pack-sizes may be marketed.
Remedica Ltd, Aharnon Street, Limassol Industrial Estate, 3056 Limassol, Cyprus
12845
Date of first authorization: 25 July 1990
Date of latest renewal: 02 December 2011
| Drug | Countries | |
|---|---|---|
| LACROMID | Cyprus |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
